Filing context and reporting period
The supplied filing is KemPharm, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, filed March 10, 2017. It is not a standalone fourth-quarter report. The request identifies Zevra Therapeutics, Inc.; that name does not match the registrant named in this filing, so confirm the intended company and filing.
KemPharm was a clinical-stage pharmaceutical company developing prodrugs using its Ligand Activated Therapy platform. It reported no product revenue and managed its operations as one segment.
Financial performance and position
- Revenue: $0 in 2016, 2015 and 2014. Gross margin is not applicable.
- 2016 operating results: Research and development expense was $20.5 million, general and administrative expense was $14.0 million, and severance expense was $3.0 million. Total operating expenses and operating loss were $37.5 million. Net loss was $16.5 million, or $1.13 per share.
- Quarterly context: In Q4 2016, operating loss was $10.8 million and net loss was $9.9 million. Q3 2016 included a $3.0 million severance charge; Q2 reported net income of $9.8 million, largely reflecting noncash fair-value movements.
- Year-over-year change: Net loss narrowed from $54.7 million in 2015, despite a $14.7 million increase in operating loss. The improvement primarily reflected a $59.7 million favorable change in the fair-value adjustment for derivative and warrant liabilities; it did not represent improved operating performance.
- Cash flow: Cash used in operations was $29.8 million, versus $20.3 million in 2015. Investing activities used $46.9 million, mainly reflecting purchases of marketable securities and long-term investments, partly offset by maturities. Financing provided $61.2 million, principally from the 2021 convertible-note offering.
- Liquidity: At year-end, the balance sheet reported $16.8 million cash and equivalents, $1.1 million restricted cash, $51.0 million marketable securities and $8.2 million long-term investments. Management said available cash and investments were expected to fund operating and capital needs through Q2 2019, subject to assumptions and continued development spending.
- Debt: Face principal of convertible notes totaled $96.25 million: $86.25 million of 5.50% senior convertible notes due 2021 and a $10.0 million Deerfield note bearing 9.75% interest. Convertible notes were carried at $91.2 million net on the balance sheet. The 2021 notes are convertible at an initial price of about $17.11 per share; the Deerfield note is convertible at $5.85 per share. Total liabilities were $103.6 million, compared with total assets of $84.9 million; stockholders’ deficit was $18.7 million.
Material changes and notable items
- R&D expense rose $6.5 million year over year, including a $3.5 million payment to license abuse-deterrent technology, higher personnel costs, and costs related to the FDA advisory committee process. G&A expense increased $5.1 million, including higher stock compensation, staffing and pre-commercialization costs.
- In September 2016, the company deferred commercial operations and redirected resources toward pipeline development. It reduced its workforce by three employees and recorded $3.0 million in severance expense, including $1.9 million of accelerated stock compensation.
- The 2016 net result included a $32.5 million favorable fair-value adjustment and a $4.7 million loss on extinguishment of debt related to repayment of the Deerfield term note. These items materially affected reported earnings.
- The company issued $86.25 million principal amount of 2021 notes in February 2016, receiving approximately $82.8 million net proceeds and using approximately $18.6 million to repay the Deerfield term note and related amounts.
Outlook, risks and contingencies
- Apadaz: The FDA issued a complete response letter in June 2016, stating that proposed labeling did not accurately convey the abuse-deterrence study results. After an August meeting, KemPharm submitted a formal dispute resolution request in November; the company estimated the process could take up to 12 months and cautioned approval, particularly with abuse-deterrence claims, was uncertain.
- Pipeline plans: Management anticipated additional KP415 pharmacokinetic data in 2017 and pivotal efficacy data in 2018, with an NDA targeted for 2018. For KP201/IR (APAP-free), it anticipated human proof-of-concept data in 2017 and an NDA in 2018. KP511/ER and KP511/IR were targeted for human proof-of-concept data in 2018 and potential NDAs in 2019. These are management expectations, not guarantees.
- Funding and execution: The company expected continued losses and substantial additional funding needs. Its stated runway does not eliminate the risk that spending, trial requirements or timing could shorten it. Equity or debt financing could dilute shareholders or add constraints.
- Development and regulatory risks: Product candidates remained investigational; clinical success, FDA approval and abuse-deterrent labeling were uncertain. Most candidates could face controlled-substance scheduling, DEA quotas, REMS requirements and manufacturing or supply constraints. The company relied on third-party manufacturers and had no redundant source identified for key drug substances.
- Other contingencies: A shareholder class action filed in December 2016 alleged misstatements or omissions in IPO offering materials. It was at a preliminary stage, damages were not quantified, and the company said it could not predict the outcome or material effect. No contingency accrual was recorded at year-end.
- Audit and controls: The auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an ICFR attestation.
Investor facts to verify
- Confirm that KemPharm’s 2016 10-K—not a Zevra Therapeutics filing—is the intended subject.
- Check subsequent FDA actions on Apadaz and whether any abuse-deterrent claims were ultimately permitted.
- Test the Q2 2019 runway estimate against actual cash burn, investment liquidity, financing and development costs.
- Review debt terms, interest obligations, conversion dilution, maturity/refinancing exposure and any later financing.
- Track whether the stated KP415, KP201/IR and KP511 development milestones were achieved and whether results supported later regulatory submissions.
- Review the status and resolution of the IPO-related class action and any resulting liabilities.